Published in Int J Radiat Oncol Biol Phys on March 20, 2008
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol (2010) 4.23
Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res (2010) 3.05
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07
Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology (2009) 1.84
The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology (2011) 1.80
Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol (2011) 1.46
New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol (2009) 1.36
Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia (2008) 1.34
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol (2011) 1.29
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
Angiogenesis as a therapeutic target in malignant gliomas. Oncologist (2009) 1.23
Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23
Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol (2012) 1.10
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med (2011) 1.07
Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One (2011) 1.05
Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther (2010) 1.05
Antagonism of NF-κB-up-regulated micro RNAs (miRNAs) in sporadic Alzheimer's disease (AD)-anti-NF-κB vs. anti-miRNA strategies. Front Genet (2013) 0.99
Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics (2009) 0.99
Radiotherapy and "new" drugs-new side effects? Radiat Oncol (2011) 0.98
Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Interv Neuroradiol (2010) 0.98
Current concepts in clinical radiation oncology. Radiat Environ Biophys (2013) 0.97
Molecular therapeutic targets for glioma angiogenesis. J Oncol (2010) 0.96
Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol (2012) 0.93
Antiangiogenic therapy for glioblastoma. Cancer J (2012) 0.92
Temozolomide in malignant glioma. Onco Targets Ther (2010) 0.89
Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr Oncol Rep (2008) 0.88
Radiotherapy in combination with vascular-targeted therapies. Radiol Oncol (2010) 0.86
Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets Ther (2013) 0.85
Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res (2010) 0.84
Safety of bevacizumab in patients with malignant gliomas: a systematic review. Neurol Sci (2013) 0.84
Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. Onco Targets Ther (2013) 0.84
Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. Biomed Res Int (2015) 0.83
New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco Targets Ther (2010) 0.83
Current available therapies and future directions in the treatment of malignant gliomas. Biologics (2009) 0.83
Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther (2011) 0.83
Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial. Onco Targets Ther (2014) 0.83
Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist (2015) 0.80
Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. Strahlenther Onkol (2010) 0.80
Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials. Med Sci Monit (2016) 0.79
Medical therapy of gliomas. J Neurooncol (2014) 0.79
Anti-vascular endothelial growth factor therapy for malignant glioma. Curr Neurol Neurosci Rep (2009) 0.79
Antiangiogenic therapy of brain tumors: the role of bevacizumab. Neurol Sci (2014) 0.78
Targeted therapy in the treatment of malignant gliomas. Onco Targets Ther (2009) 0.78
Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Oncotarget (2016) 0.78
Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. Radiat Oncol (2015) 0.77
Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report. BMC Cancer (2010) 0.77
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. Radiat Oncol (2013) 0.77
Two Patients With Brain Tumors Who Received Bevacizumab and Radiotherapy: Optic Neuropathy and Quality-of-Life Issues. J Adv Pract Oncol (2013) 0.76
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. J Neurooncol (2016) 0.75
Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. Perm J (2015) 0.75
A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis(†). Neurooncol Pract (2016) 0.75
Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain. Neuroradiol J (2015) 0.75
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol (2010) 4.23
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene (2003) 3.83
Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res (2006) 3.41
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Gene expression profiling identifies molecular subtypes of gliomas. Oncogene (2003) 3.13
Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res (2010) 3.05
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 2.89
Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery (2005) 2.84
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol (2007) 2.77
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke (2011) 2.52
Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab (2005) 2.52
Intensive insulin therapy reduces microdialysis glucose values without altering glucose utilization or improving the lactate/pyruvate ratio after traumatic brain injury. Crit Care Med (2006) 2.43
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med (2005) 2.36
Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics (2008) 2.29
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2010) 2.21
Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res (2006) 2.18
Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells (2009) 2.10
Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience. Epilepsia (2009) 1.99
Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res (2008) 1.96
Persistently low extracellular glucose correlates with poor outcome 6 months after human traumatic brain injury despite a lack of increased lactate: a microdialysis study. J Cereb Blood Flow Metab (2003) 1.93
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab (2013) 1.86
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol (2006) 1.79
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med (2006) 1.74
Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res (2013) 1.68
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol (2011) 1.67
Morphological clustering and analysis of continuous intracranial pressure. IEEE Trans Biomed Eng (2008) 1.67
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg (2003) 1.63
Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology (2008) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys (2012) 1.56
Hydrophilic polymer emboli: an under-recognized iatrogenic cause of ischemia and infarct. Mod Pathol (2010) 1.55
The value of supplemental prognostic tests for the preoperative assessment of idiopathic normal-pressure hydrocephalus. Neurosurgery (2005) 1.52
Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med (2008) 1.48
Challenges in linear accelerator radiotherapy for chordomas and chondrosarcomas of the skull base: focus on complications. Int J Radiat Oncol Biol Phys (2011) 1.47
Gliomas: advances in molecular analysis and characterization. Surg Neurol (2005) 1.46
Endoscope-assisted placement of a multiperforated shunt catheter into the fourth ventricle via a frontal transventricular approach. Neurosurg Focus (2007) 1.45
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A (2010) 1.45
CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One (2011) 1.44
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Energy dysfunction as a predictor of outcome after moderate or severe head injury: indices of oxygen, glucose, and lactate metabolism. J Cereb Blood Flow Metab (2003) 1.42
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids (2013) 1.40
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer (2003) 1.40
An algorithm for extracting intracranial pressure latency relative to electrocardiogram R wave. Physiol Meas (2008) 1.39
Intravascular polymer material after coil embolization of a giant cerebral aneurysm. Hum Pathol (2009) 1.38
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol (2008) 1.37
Diagnosis of meningioma by time-resolved fluorescence spectroscopy. J Biomed Opt (2006) 1.36
Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res (2007) 1.35
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res (2002) 1.33
Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res (2003) 1.32
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol (2009) 1.32
Digital microfluidic platform for multiplexing enzyme assays: implications for lysosomal storage disease screening in newborns. Clin Chem (2011) 1.31
The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol (2005) 1.31
Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys (2003) 1.30
Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro Oncol (2012) 1.28
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol (2013) 1.27
Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol (2009) 1.26
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res (2008) 1.25
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab (2013) 1.23
Estimation of hidden state variables of the Intracranial system using constrained nonlinear Kalman filters. IEEE Trans Biomed Eng (2007) 1.20
A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Res (2010) 1.20
Fluorescence lifetime spectroscopy of glioblastoma multiforme. Photochem Photobiol (2004) 1.20
Forecasting ICP elevation based on prescient changes of intracranial pressure waveform morphology. IEEE Trans Biomed Eng (2010) 1.20
Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer (2010) 1.19
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol (2012) 1.17
Regression analysis for peak designation in pulsatile pressure signals. Med Biol Eng Comput (2009) 1.16
Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med (2002) 1.14
Accuracy of a method using short inhalation of (15)O-O(2) for measuring cerebral oxygen extraction fraction with PET in healthy humans. J Nucl Med (2004) 1.13